US panel backs Theratechnologies' Egrifta for HIV lipodystrophy
This article was originally published in Scrip
Executive Summary
Theratechnologies' Egrifta (tesamorelin acetate for injection) should be approved for treatment of HIV-related lipodystrophy, although the drug's cardiovascular impacts require extensive post-approval study, the US FDA's outside advisors said on 27 May.